These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 1250044)

  • 1. [Chemical diagnosis of melanoma].
    Agrup G
    Lakartidningen; 1976 Feb; 73(7):526-8. PubMed ID: 1250044
    [No Abstract]   [Full Text] [Related]  

  • 2. [Urinary 5-S-cysteinyldopa levels in patients with malignant melanoma. Preliminary results].
    Césarini JP; Meunier M
    Rev Prat; 1975 Nov; 25(51):4037-9. PubMed ID: 1209143
    [No Abstract]   [Full Text] [Related]  

  • 3. 5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis.
    Agrup G; Agrup P; Andersson T; Hafström L; Hansson C; Jacobsson S; Jönsson PE; Rorsman H; Rosengren AM; Rosengren E
    Acta Derm Venereol; 1979; 59(5):381-8. PubMed ID: 93360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Melanoma metabolites (proceedings)].
    Rorsman H
    Lakartidningen; 1978 Dec; 75(49):4596-7. PubMed ID: 723347
    [No Abstract]   [Full Text] [Related]  

  • 5. [Comparative studies between excretion of 5-S-cysteinyldopa and indole melanogens in urine].
    Beyer C; Fiedler H; Wohlrab W; Wozniak KD
    Dermatol Monatsschr; 1986; 172(9):541-4. PubMed ID: 3098590
    [No Abstract]   [Full Text] [Related]  

  • 6. 5-S-cysteinyldopa in the plasma of melanoma patients and the renal clearance of this amino acid.
    Agrup G; Andersson T; Falck B; Persson K; Rorsman H; Rosengren AM; Rosengren E
    Acta Derm Venereol; 1975; 55(1):5-6. PubMed ID: 46673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-S-cysteinyldopa in the urine of melanoma patients.
    Agrup G; Agrup P; Andersson T; Falck B; Hansson JA; Jacobsson S; Rorsman H; Rosengren E; Rosengren AM
    Acta Derm Venereol; 1977; 57(2):113-6. PubMed ID: 71802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [5-S-cysteinyldopa determination in the urine. Its value for monitoring in melanoma patients].
    Paul E; Graef V; Ruppel R; Hellwich M
    Z Hautkr; 1983 Feb; 58(4):262-5. PubMed ID: 6405551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Demonstration of 3-methoxytyrosine in the urine of melanoma patients.
    Agrup G; Bengtsson M; Falck B; Persson K; Rorsman H; Rosengren AM; Rosengren E
    Acta Derm Venereol; 1976; 56(1):27-31. PubMed ID: 56853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [5-S-cysteinyldopa in the urine - a "tumor test" for malignant melanoma? Comparison with the usual laboratory examinations].
    Paul E; Graef V; Ruppel R
    Z Hautkr; 1980 Dec; 55(23):1543-60. PubMed ID: 6782780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Urinary 5-S-cysteinyldopa in malignant melanoma subjects-with special reference to melanoma stages and dopa loading test (author's transl)].
    Ichihasi M; Mojamdar M; Mishima Y
    Nihon Hifuka Gakkai Zasshi; 1981 Sep; 91(10):1045-9. PubMed ID: 6798247
    [No Abstract]   [Full Text] [Related]  

  • 12. The melanocyte illuminated.
    Rorsman H
    Trans St Johns Hosp Dermatol Soc; 1974; 60(2):135-41. PubMed ID: 4467885
    [No Abstract]   [Full Text] [Related]  

  • 13. Cysteinyldopa isomers and dopa in lesions and urine of Japanese patients with malignant melanoma.
    Morishima T; Tatsumi F; Fukada E; Saito M; Fujita M; Nagashima N; Hanawa S
    Arch Dermatol Res; 1983; 275(2):76-9. PubMed ID: 6409012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Contemporary possibilities of the biochemical diagnosis of malignant melanoma (author's transl)].
    Matous B; Janderová M; Mechl Z; Pavel S; Duchon J
    Sb Lek; 1977; 79(11-12):356-61. PubMed ID: 601505
    [No Abstract]   [Full Text] [Related]  

  • 15. Urinary 5-S-cysteinyldopa in Parkinsonism after DOPA and carbidopa.
    Stewart RM; Miller S; Gunder M
    Acta Derm Venereol; 1983; 63(2):97-101. PubMed ID: 6189350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formation of cysteinyldopa from glutathionedopa in melanoma.
    Agrup G; Falck B; Kennedy BM; Rorsman H; Rosengren AM; Rosengren E
    Acta Derm Venereol; 1975; 55(1):1-3. PubMed ID: 46665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relations between the elimination of indolmelanogens and hydroxyindol particles in urine].
    Schwartze G
    Dermatol Monatsschr; 1970; 156(5):361-6. PubMed ID: 5509133
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical significance of tests for Thormählen-positive melanogen excretion in malignant melanoma].
    Matous B; Budĕsínská A; Mechl Z; Sopková B; Pavel S; Duchon J
    Cesk Dermatol; 1980 Aug; 55(4):238-41. PubMed ID: 7407958
    [No Abstract]   [Full Text] [Related]  

  • 19. Simple screening test for estimation of some phenolic and indolic compounds in urine application to melanoma.
    Pavel S; Matous B; Duchon J
    J Invest Dermatol; 1978 Apr; 70(4):197-9. PubMed ID: 641370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Increased excretion of indolemelanogens in malignant melanoma without liver metastasis].
    Schwartze G; Haneke E
    Dermatol Monatsschr; 1969; 155(2):99-102. PubMed ID: 5386292
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.